Genini Davide, Catapano Carlo V
Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland.
J Biol Chem. 2007 Apr 20;282(16):11776-85. doi: 10.1074/jbc.M609149200. Epub 2007 Feb 26.
Peroxisome proliferator-activated receptor delta (PPARdelta) is a ligand-activated transcription factor involved in many physiological and pathological processes. PPARdelta is a promising therapeutic target for metabolic, chronic inflammatory, and neurodegenerative disorders. However, limited information is available about the mechanisms that control the activity of this nuclear receptor. Here, we examined the role of the ubiquitinproteasome system in PPARdelta turnover. The receptor was ubiquitinated and subject to rapid degradation by the 26 S proteasome. Unlike most nuclear receptors that are degraded upon ligand binding, PPARdelta ligands inhibited the ubiquitination of the receptor, thereby preventing its degradation. Ligand binding was required for inhibition of the ubiquitination since disruption of the ligand binding domain abolished the effect. Site-directed mutagenesis showed that the DNA binding domain was also required, indicating that ligands preferentially stabilized the DNA-bound receptor. In contrast, the activation function-2 domain and co-repressor binding site were not involved in ligand-induced stabilization. Block of ubiquitination by ligands may be an essential step to avoid rapid degradation of a receptor, like PPARdelta, with a very short half-life and sustain its transcriptional activity once it is engaged in transcriptional activation complexes.
过氧化物酶体增殖物激活受体δ(PPARδ)是一种参与多种生理和病理过程的配体激活转录因子。PPARδ是代谢、慢性炎症和神经退行性疾病的一个有前景的治疗靶点。然而,关于控制这种核受体活性的机制的信息有限。在这里,我们研究了泛素-蛋白酶体系统在PPARδ周转中的作用。该受体被泛素化并被26S蛋白酶体快速降解。与大多数在配体结合后被降解的核受体不同,PPARδ配体抑制受体的泛素化,从而防止其降解。抑制泛素化需要配体结合,因为配体结合域的破坏消除了这种作用。定点诱变表明还需要DNA结合域,这表明配体优先稳定结合DNA的受体。相比之下,激活功能-2结构域和共抑制因子结合位点不参与配体诱导的稳定作用。配体对泛素化的阻断可能是避免像PPARδ这样半衰期非常短的受体快速降解,并在其参与转录激活复合物后维持其转录活性的一个重要步骤。